Where will leukemia research go next?
Why is it important to risk stratify patients in CLL?
The differences in treating older versus younger CLL patients
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
Why the rapid development of new drugs poses new challenges